Terns Pharmaceuticals, Inc.
TERNNASDAQHealthcare
$52.95
$-0.02(-0.03%)
Market Cap$4.8B
P/E Ratio—
52W High$53.19
52W Low$2.655
Terns Pharmaceuticals, Inc. (TERN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
TERN · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$0.26
Est. -$0.30 · +13.3%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▲ Beat EPS🔥 10-Quarter EPS Beat Streak
TERN reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 14, 2026 | -$0.30 | -$0.26 | +13.3% | — | — | — |
| ▲ Q1 FY2026 | Mar 30, 2026 | -$0.29 | -$0.25 | +13.8% | — | — | — |
| ▲ Q4 FY2025 | Nov 10, 2025 | -$0.30 | -$0.27 | +10.0% | — | — | — |
| ▲ Q3 FY2025 | Aug 5, 2025 | -$0.28 | -$0.26 | +7.1% | — | — | — |
| ▲ Q2 FY2025 | May 8, 2025 | -$0.29 | -$0.26 | +10.3% | — | — | — |
| ▲ Q1 FY2025 | Mar 20, 2025 | -$0.30 | -$0.24 | +20.0% | — | — | — |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$0.33 | -$0.28 | +15.2% | — | — | — |
| ▲ Q3 FY2024 | Aug 5, 2024 | -$0.35 | -$0.31 | +11.4% | — | — | — |
Q2 FY2026
May 14, 2026Beat
EPS Actual
-$0.26
EPS Est.
-$0.30
EPS Surpr.
+13.3%
Revenue
—
Q1 FY2026
Mar 30, 2026Beat
EPS Actual
-$0.25
EPS Est.
-$0.29
EPS Surpr.
+13.8%
Revenue
—
Q4 FY2025
Nov 10, 2025Beat
EPS Actual
-$0.27
EPS Est.
-$0.30
EPS Surpr.
+10.0%
Revenue
—
Q3 FY2025
Aug 5, 2025Beat
EPS Actual
-$0.26
EPS Est.
-$0.28
EPS Surpr.
+7.1%
Revenue
—
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$0.26
EPS Est.
-$0.29
EPS Surpr.
+10.3%
Revenue
—
Q1 FY2025
Mar 20, 2025Beat
EPS Actual
-$0.24
EPS Est.
-$0.30
EPS Surpr.
+20.0%
Revenue
—
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$0.28
EPS Est.
-$0.33
EPS Surpr.
+15.2%
Revenue
—
Q3 FY2024
Aug 5, 2024Beat
EPS Actual
-$0.31
EPS Est.
-$0.35
EPS Surpr.
+11.4%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.32 | $-0.32 | $-0.32 | 1 |
| Q3 FY2028 | $-0.33 | $-0.33 | $-0.33 | 1 |
| Q2 FY2028 | $-0.33 | $-0.33 | $-0.33 | 1 |
| Q1 FY2028 | $-0.33 | $-0.33 | $-0.33 | 1 |
| Q4 FY2027 | $-0.41 | $-0.41 | $-0.41 | 1 |
| Q3 FY2027 | $-0.35 | $-0.35 | $-0.35 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 14, 2026 | +13.3% | $52.95 | $52.95 | +0.00% |
| ▲ Q1 FY2026 | Mar 30, 2026 | +13.8% | $52.92 | $52.88 | -0.08% |
| ▲ Q4 FY2025 | Nov 10, 2025 | +10.0% | $18.47 | $19.12 | +3.52% |
| ▲ Q3 FY2025 | Aug 5, 2025 | +7.1% | $5.75 | $6.08 | +5.74% |
| ▲ Q2 FY2025 | May 8, 2025 | +10.3% | $3.03 | $3.00 | -0.99% |
| ▲ Q1 FY2025 | Mar 20, 2025 | +20.0% | $3.16 | $3.14 | -0.63% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +15.2% | $7.46 | $7.17 | -3.89% |
| ▲ Q3 FY2024 | Aug 5, 2024 | +11.4% | $7.46 | $7.31 | -2.01% |
Q2 FY2026+0.00%
Report Date
May 14, 2026
EPS Beat/Miss
+13.3%
Price Before
$52.95
Price After
$52.95
Q1 FY2026-0.08%
Report Date
Mar 30, 2026
EPS Beat/Miss
+13.8%
Price Before
$52.92
Price After
$52.88
Q4 FY2025+3.52%
Report Date
Nov 10, 2025
EPS Beat/Miss
+10.0%
Price Before
$18.47
Price After
$19.12
Q3 FY2025+5.74%
Report Date
Aug 5, 2025
EPS Beat/Miss
+7.1%
Price Before
$5.75
Price After
$6.08
Q2 FY2025-0.99%
Report Date
May 8, 2025
EPS Beat/Miss
+10.3%
Price Before
$3.03
Price After
$3.00
Q1 FY2025-0.63%
Report Date
Mar 20, 2025
EPS Beat/Miss
+20.0%
Price Before
$3.16
Price After
$3.14
Q4 FY2024-3.89%
Report Date
Nov 12, 2024
EPS Beat/Miss
+15.2%
Price Before
$7.46
Price After
$7.17
Q3 FY2024-2.01%
Report Date
Aug 5, 2024
EPS Beat/Miss
+11.4%
Price Before
$7.46
Price After
$7.31
Avg Beat Reaction+0.21%
Beat Rate8 / 8 quarters
Largest Move+5.74% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: TERN ends December
Terns Pharmaceuticals, Inc. (TERN) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-0.26 — beating the analyst consensus of $-0.30 by +13.3%. TERN has beaten EPS estimates for 10 consecutive quarters. The next TERN earnings date is expected around September 1, 2026.
Each quarter, investors track TERN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. TERN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
TERN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
TERN earnings · 5 questionsTerns Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. TERN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; TERN historically reports after market close (AMC).
TERN earnings datewhen is TERN earningsTERN next earnings datewhen does TERN report earningsTERN earnings calendar
▸ Source: FMP · Terns Pharmaceuticals, Inc. SEC filings · US GAAP · Terns Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026